CY1117691T1 - Υπερκορεσμενο ενεσιμο διαλυμα ακεταμινοφαινης για νωτιαια χορηγηση - Google Patents

Υπερκορεσμενο ενεσιμο διαλυμα ακεταμινοφαινης για νωτιαια χορηγηση

Info

Publication number
CY1117691T1
CY1117691T1 CY20161100584T CY161100584T CY1117691T1 CY 1117691 T1 CY1117691 T1 CY 1117691T1 CY 20161100584 T CY20161100584 T CY 20161100584T CY 161100584 T CY161100584 T CY 161100584T CY 1117691 T1 CY1117691 T1 CY 1117691T1
Authority
CY
Cyprus
Prior art keywords
solution
acutaminofein
supplementary
local administration
acetaminophen
Prior art date
Application number
CY20161100584T
Other languages
Greek (el)
English (en)
Inventor
Augusto Mitidieri
Elisabetta Donati
Nicola Caronzolo
Original Assignee
Sintetica S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117691(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sintetica S.A. filed Critical Sintetica S.A.
Publication of CY1117691T1 publication Critical patent/CY1117691T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20161100584T 2012-06-29 2016-06-28 Υπερκορεσμενο ενεσιμο διαλυμα ακεταμινοφαινης για νωτιαια χορηγηση CY1117691T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001154A ITMI20121154A1 (it) 2012-06-29 2012-06-29 Soluzione iniettabile di acetaminofene per la somministrazione spinale
PCT/IB2013/055277 WO2014002042A1 (en) 2012-06-29 2013-06-27 Injectable supersaturated acetaminophen solution for spinal administration

Publications (1)

Publication Number Publication Date
CY1117691T1 true CY1117691T1 (el) 2017-05-17

Family

ID=46690603

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100584T CY1117691T1 (el) 2012-06-29 2016-06-28 Υπερκορεσμενο ενεσιμο διαλυμα ακεταμινοφαινης για νωτιαια χορηγηση

Country Status (44)

Country Link
US (2) US11344517B2 (OSRAM)
EP (1) EP2874602B1 (OSRAM)
JP (1) JP5876620B2 (OSRAM)
KR (1) KR102118227B1 (OSRAM)
CN (1) CN104487051B (OSRAM)
AP (1) AP2014008152A0 (OSRAM)
AR (1) AR091633A1 (OSRAM)
AU (1) AU2013282753B2 (OSRAM)
BR (1) BR112014032818B1 (OSRAM)
CA (1) CA2876801C (OSRAM)
CL (1) CL2014003536A1 (OSRAM)
CO (1) CO7240357A2 (OSRAM)
CR (1) CR20150036A (OSRAM)
CU (1) CU20140150A7 (OSRAM)
CY (1) CY1117691T1 (OSRAM)
DK (1) DK2874602T3 (OSRAM)
DO (1) DOP2014000302A (OSRAM)
EA (1) EA028909B1 (OSRAM)
EC (1) ECSP15000500A (OSRAM)
ES (1) ES2578012T3 (OSRAM)
GE (1) GEP201706689B (OSRAM)
HR (1) HRP20160706T1 (OSRAM)
HU (1) HUE029431T2 (OSRAM)
IL (1) IL236423A (OSRAM)
IT (1) ITMI20121154A1 (OSRAM)
MA (1) MA37811B1 (OSRAM)
MD (1) MD4537C1 (OSRAM)
ME (1) ME02431B (OSRAM)
MX (1) MX369264B (OSRAM)
MY (1) MY169251A (OSRAM)
NI (1) NI201400147A (OSRAM)
NZ (1) NZ703829A (OSRAM)
PE (1) PE20150331A1 (OSRAM)
PH (1) PH12015500178B1 (OSRAM)
PL (1) PL2874602T3 (OSRAM)
PT (1) PT2874602T (OSRAM)
RS (1) RS54844B1 (OSRAM)
SG (2) SG11201408479WA (OSRAM)
SI (1) SI2874602T1 (OSRAM)
SM (1) SMT201600248B (OSRAM)
TN (1) TN2014000526A1 (OSRAM)
UA (1) UA117101C2 (OSRAM)
WO (1) WO2014002042A1 (OSRAM)
ZA (1) ZA201409478B (OSRAM)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0646400B1 (en) * 1993-04-14 2001-07-18 Nippon Sanso Corporation Dissolved oxygen reducing apparatus
US6171298B1 (en) * 1996-05-03 2001-01-09 Situs Corporation Intravesical infuser
FR2751875B1 (fr) 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
DE10112325A1 (de) * 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
RS53804A (sr) * 2001-12-18 2006-12-15 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Parenteralna kompozicija paracetamola
FR2851164B1 (fr) 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
DE102005037653A1 (de) * 2005-08-05 2007-02-15 Theraselect Gmbh Stabile, flüssige Formulierung von Paracetamol
JP4929352B2 (ja) * 2006-07-18 2012-05-09 スペイン ファルマ ソシエダ アノニマ 注入可能なパラセタモール液剤
CN101015542A (zh) * 2007-02-13 2007-08-15 天津生机集团有限公司 家畜用复方对乙酰氨基酚注射液及其制备方法
MD3528G2 (ro) * 2007-09-28 2008-11-30 Сергей ШАНДРУ Metodă de anestezie spinală continuă la pacienţii în etate
WO2009064928A1 (en) * 2007-11-13 2009-05-22 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
EP2307056B1 (en) 2008-01-17 2021-12-15 Pharmis Biofarmacêutica, LDA Stabilized aqueous formulation containing paracetamol
WO2009143558A1 (en) 2008-05-26 2009-12-03 Silphion Pty Limited Injectable formulations
EP2243477A1 (de) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracetamol zur parenteralen Verabreichung
JP2013006770A (ja) 2009-10-09 2013-01-10 Ssp Co Ltd アセトアミノフェン含有経口液剤
BR112012031928B1 (pt) * 2010-06-30 2021-08-31 Troikaa Pharmaceuticals Ltd Composições farmacêuticas as quais incluem paracetamol e processo para preparação do mesmo

Also Published As

Publication number Publication date
AU2013282753B2 (en) 2017-03-02
CN104487051B (zh) 2017-12-12
DOP2014000302A (es) 2015-03-15
NI201400147A (es) 2015-04-13
SMT201600248B (it) 2016-08-31
CN104487051A (zh) 2015-04-01
MA37811A1 (fr) 2016-10-31
CL2014003536A1 (es) 2015-05-08
MX369264B (es) 2019-11-04
ECSP15000500A (es) 2015-11-30
MA37811B1 (fr) 2017-07-31
PL2874602T3 (pl) 2016-10-31
ITMI20121154A1 (it) 2013-12-30
NZ703829A (en) 2016-06-24
GEP201706689B (en) 2017-06-26
SG11201408479WA (en) 2015-01-29
AR091633A1 (es) 2015-02-18
RS54844B1 (sr) 2016-10-31
IL236423A0 (en) 2015-02-26
MD4537C1 (ro) 2018-07-31
AU2013282753A1 (en) 2015-02-05
US20160128955A1 (en) 2016-05-12
BR112014032818B1 (pt) 2022-06-14
AP2014008152A0 (en) 2014-12-31
SI2874602T1 (sl) 2016-09-30
IL236423A (en) 2017-07-31
PT2874602T (pt) 2016-07-13
CA2876801A1 (en) 2014-01-03
CU20140150A7 (es) 2015-10-27
US20150148379A1 (en) 2015-05-28
WO2014002042A1 (en) 2014-01-03
CO7240357A2 (es) 2015-04-17
PH12015500178B1 (en) 2021-08-04
KR20150027160A (ko) 2015-03-11
TN2014000526A1 (en) 2016-03-30
ZA201409478B (en) 2016-01-27
JP5876620B2 (ja) 2016-03-02
EP2874602B1 (en) 2016-03-30
JP2015522004A (ja) 2015-08-03
EP2874602A1 (en) 2015-05-27
MD4537B1 (ro) 2017-12-31
KR102118227B1 (ko) 2020-06-03
ME02431B (me) 2016-09-20
MY169251A (en) 2019-03-19
UA117101C2 (uk) 2018-06-25
MD20140138A2 (ro) 2015-06-30
CR20150036A (es) 2015-03-13
PE20150331A1 (es) 2015-03-07
ES2578012T3 (es) 2016-07-20
EA201500065A1 (ru) 2015-10-30
EA028909B1 (ru) 2018-01-31
BR112014032818A2 (pt) 2017-06-27
SG10201704482YA (en) 2017-07-28
MX2014015402A (es) 2015-06-17
DK2874602T3 (en) 2016-07-04
HRP20160706T1 (hr) 2016-08-12
CA2876801C (en) 2020-11-03
US11344517B2 (en) 2022-05-31
PH12015500178A1 (en) 2015-04-06
HUE029431T2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1125290T1 (el) Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1121150T1 (el) Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας
MX2021005561A (es) Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco.
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
CY1119676T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
CR20140410A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
BR112015025354A2 (pt) compostos di-hidropirido-pirimidínicos como inibidores de autotaxina
DK3193981T3 (da) Medikamentadministrationsanordning i form af voluminøst hudplaster med integreret mekanisme til hudsterilisering af injektionssted
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
MX2017012926A (es) Inhibidores y sus usos.
CY1123243T1 (el) Ενωση προερχομενη απο πυραζολινη και η χρηση τησσε ενα θεραπευτικο σχημα εβδομαδιαιας δοσολογησης εναντια στην φλεγμονη και τον πονο που προερχονται απο την εκφυλιστικη ασθενεια των αρθρωσεων στα θηλαστικα
CY1122042T1 (el) Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο
CY1119413T1 (el) Μεθοδος για την παραγωγη και τη χρηση ενος συμπολυμερους νατριουχου καρβοξυμεθυλοκυτταρινης και γκοσυπολης
CY1121773T1 (el) Χρηση του παλμιτοϋλοαιθανολαμιδιου σε συνδυασμο με οπιοειδη
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico